Scynexis Inc Asset Resilience Ratio
Scynexis Inc asset resilience ratio. Scynexis Inc (SCYX) has an Asset Resilience Ratio of 58.15% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Scynexis Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Scynexis Inc (2014–2025)
Asset resilience ratio of Scynexis Inc from 2014 to 2025. This chart shows how Scynexis Inc's Asset Resilience Ratio has changed over time. Read SCYX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Scynexis Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see SCYX total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $43.60 Million | 58.15% |
| Total Liquid Assets | $43.60 Million | 58.15% |
Asset Resilience Insights
- Very High Liquidity: Scynexis Inc maintains exceptional liquid asset reserves at 58.15% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Scynexis Inc Industry Peers by Asset Resilience Ratio
Compare Scynexis Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Nhwa Pharmaceutical Co Ltd
SHE:002262 |
Drug Manufacturers - Specialty & Generic | 26.45% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 11.84% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Bide Pharmatech Co. Ltd. A
SHG:688073 |
Drug Manufacturers - Specialty & Generic | 9.46% |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976 |
Drug Manufacturers - Specialty & Generic | 20.61% |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365 |
Drug Manufacturers - Specialty & Generic | 30.38% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.42% |
Scynexis Inc Asset Resilience Ratio by Year (2014–2025)
Scynexis Inc asset resilience ratio by year from 2014 to 2025. The table below shows the annual Asset Resilience Ratio data for Scynexis Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 31.80% | $18.77 Million | $59.03 Million | -15.91pp |
| 2024-12-31 | 47.71% | $43.25 Million | $90.64 Million | +16.32pp |
| 2023-12-31 | 31.39% | $40.31 Million | $128.41 Million | -0.14pp |
| 2022-12-31 | 31.53% | $27.69 Million | $87.81 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $119.84 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $102.54 Million | -- |
| 2019-12-31 | 11.36% | $6.49 Million | $57.15 Million | -50.17pp |
| 2018-12-31 | 61.53% | $32.72 Million | $53.17 Million | -9.18pp |
| 2017-12-31 | 70.72% | $32.42 Million | $45.85 Million | +32.37pp |
| 2016-12-31 | 38.35% | $22.93 Million | $59.79 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $49.27 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $39.67 Million | -- |
About Scynexis Inc
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the tre… Read more